Metagenomi logo
Metagenomi
MGX | NASDAQ
Chart Builder DCF Calculator
$0.68
-$0.01 (-1.69%)
At close: Nov 16, 2026, 4:00 PM ET
$0.66
-$0.02 (-3.38%)
After-hours: Nov 16, 2026, 6:18 PM ET

Metagenomi Company Profile

Company profile explained

Company Profile

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

Key Executives

Name Position
Jian Irish CEO, President & Director
Pamela Wapnick Chief Financial Officer
Alan Brooks Senior Vice President of Research
Joseph Knowles Co-Founder & Member of Scientific Advisory Board
Katalin Kauser Senior Vice Pres­i­dent of Trans­la­tion­al Biol­o­gy
Mark Leonard Senior Vice Pres­i­dent of Tech­ni­cal Devel­op­ment & Oper­a­tions
Matthew L. Wein Gen­er­al Coun­sel, Com­pli­ance Offi­cer, Head of BD&L and Cor­po­rate Secretary
Nikhil Bhide Senior Vice President of Business Development

Latest SEC Filings

Date Type Title
Sep 22, 2026 8-K Current Report
Sep 11, 2026 4 Filing
Sep 10, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 10, 2026 4 Filing
Sep 10, 2026 4 Filing
Sep 10, 2026 4 Filing
Aug 10, 2026 10-Q Quarterly Report
Aug 10, 2026 8-K Current Report
Jun 11, 2026 4 Filing
Jun 11, 2026 4 Filing
View All SEC Filings ➞
Metagenomi
Metagenomi logo
Country United States
IPO Date Feb 9, 2024
Industry Biotechnology
Sector Healthcare
Employees 113
CEO Jian Irish

Contact Details

5959 Horton Street Emeryville, California 94608 United States

Stock Details

Ticker Symbol MGX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001785279
CUSIP Number 59102M104
ISIN Number US59102M1045
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.